Security key
86889P117
- Security type / class
- Equity / *W EXP 08/01/203
- Total 13F shares
- 2,921,496
- Total 13F value
- $176,469
- Share change
- +43,875
- SEC-reported price per share
- $0.02
- Number of holders
- 16
- Value change
- +$1,036
- Number of buys
- 3
Report period
Q1 2026
Institutions
16
Top holders
10
SRZNW full security history
Ownership snapshot
Full 13F holder table
Surrozen, Inc./DE SEC filings
Surrozen, Inc./DE company facts
Broader feeds
Ownership snapshot
Top reported holders of SRZNW - Surrozen, Inc./DE - *W EXP 08/01/203 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Venrock Healthcare Capita...
Disclosed value leader
Column Group LLC
Comparable rows
10/15
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 9.9%
5 rows are not safely comparable across share classes.
13D/G row: Venrock Healthcare Capital Partners III, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Venrock Healthcare Capital Partners III, L.P. leads the comparable SEC ownership view at 9.9%.
10 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Venrock Healthcare Capital Partners III, L.P.'s linked filing trail.
Comparable ownership
Top 5
Venrock Healthcare Capital Partne...
9.9%
AI Biotechnology LLC
9.9%
RA CAPITAL MANAGEMENT, L.P.
9.2%
INTEGRATED CORE STRATEGIES (US) LLC
8.5%
Stonepine Capital Management, LLC
3.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
9.9%
Reported 13D/G
· 31 Mar 2026
|
$35,981,300
1,205,000 shares
|
+$9,927,076 | 31 Mar 2026 |
| AI Biotechnology LLC |
13D/G
|
9.9%
Reported 13D/G
· 24 Mar 2025
|
$8,462,521
844,563 shares
|
$0 | 24 Mar 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
9.2%
Reported 13D/G
· 31 Dec 2025
|
$18,001,245
871,731 shares
|
+$89,063 | 31 Dec 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
8.5%
Reported 13D/G
· 31 Dec 2025
|
$15,649,459
726,193 shares
|
+$3,477,006 | 31 Dec 2025 |
| Stonepine Capital Management, LLC |
13D/G
13F
Company
|
3.6%
Reported 13D/G
· 31 Dec 2025
|
$6,531,368
316,289 shares
|
-$3,973,019 | 31 Dec 2025 |
| Nantahala Capital Partners Limited Partnership |
13D/G
|
2.2%
Reported 13D/G
· 31 Mar 2025
|
$740,658
73,918 shares
|
-$1,032,581 | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
16
Shares
2,921,496
Rows available
16
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
16
Q1 2026 holders
16
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|